; INH, isoniazid; MDR, multidrug resistant; mono, monoresistant; RIF, rifampin; SM, streptomycin; XDR, extensively drug resistant.
Further, in isolation, streptomycin showed highest resistance of 4.6% followed by rifampicin 4.0%, isoniazid 3.7% and ethambutol
Visual evoked potentials in the detection of subclinical optic toxic effects secondary to ethambutol
. Arch Neurol 1983;40:645-8.
We compared moxifloxacin based regimen (combination of isoniazid, rifampin, pyrazinamide, moxifloxacin) with standard treatment (combination of isoniazid, rifampin, pyrazinamide, ethambutol
) for TBM.
Abbreviations CNS: Central nervous system ETH: Ethambutol
INH: Isoniazid MDR-TB: Multidrug resistant tuberculosis Moxi: Moxifloxacin NAT: Nucleic acid testing PCR: Polymerase chain reaction PHESS: Public Health Event Surveillance System PZE: Pyrazinamide RIF: Rifampicin TB: Tuberculosis XDR-TB: Extensively drug resistant tuberculosis.
also has been reported to cause AKI , it is more commonly known to cause ocular optic neuropathy .
He had also received 4 months of INH and 2 months of ethambutol
, which may not have significantly contributed to his resolution.
Safi H, Fleischmann RD, Peterson SN, Jones MB, Jarrahi B, AllandD.Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol
in Mycobacterium tuberculosis.
Diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol
with genotype MTBDRsl assay: A meta-analysis.
tuberculosis for susceptibility against isoniazid, rifampicin, ethambutol
, and streptomycin.
MDR, KMRC 00116-00250, pathogenic-resistant to isoniazid, rifampicin, streptomycin, and pyrazinamide; XDR, KMRC 00203- 00197, pathogenic-resistant to isoniazid, rifampicin, ethambutol
, kanamycin, ofloxacin, rifabutin and amikacin, but susceptible to capreomycin, streptomycin, moxifloxacin, prothionamide, p-aminosalicylic, and cycloserine.
Fifty-five Thai patients with tuberculosis were randomly assigned to receive, in double-blind fashion, 140 mg of silymarin 3 times per day or placebo, in addition to a standard antituberculosis treatment regimen of isoniazid (5 mg/kg/day), rifampicin (10 mg/ kg/day), pyrazinamide (25 mg/kg/day), and ethambutol
(15 mg/ kg/day).